NEURONETICS INC (STIM) Fundamental Analysis & Valuation

NASDAQ:STIM • US64131A1051

Current stock price

1.29 USD
-0.04 (-3.01%)
At close:
1.2995 USD
+0.01 (+0.74%)
After Hours:

This STIM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. STIM Profitability Analysis

1.1 Basic Checks

  • In the past year STIM has reported negative net income.
  • STIM had a negative operating cash flow in the past year.
  • In the past 5 years STIM always reported negative net income.
  • STIM had a negative operating cash flow in each of the past 5 years.
STIM Yearly Net Income VS EBIT VS OCF VS FCFSTIM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M

1.2 Ratios

  • STIM has a Return On Assets (-27.55%) which is comparable to the rest of the industry.
  • Looking at the Return On Equity, with a value of -174.27%, STIM is doing worse than 73.02% of the companies in the same industry.
Industry RankSector Rank
ROA -27.55%
ROE -174.27%
ROIC N/A
ROA(3y)-28.21%
ROA(5y)-27.7%
ROE(3y)-140.11%
ROE(5y)-104.4%
ROIC(3y)N/A
ROIC(5y)N/A
STIM Yearly ROA, ROE, ROICSTIM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 200

1.3 Margins

  • STIM's Gross Margin of 48.48% is in line compared to the rest of the industry. STIM outperforms 44.97% of its industry peers.
  • In the last couple of years the Gross Margin of STIM has declined.
  • STIM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.01%
GM growth 5Y-8.73%
STIM Yearly Profit, Operating, Gross MarginsSTIM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. STIM Health Analysis

2.1 Basic Checks

  • STIM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for STIM has been increased compared to 1 year ago.
  • Compared to 5 years ago, STIM has more shares outstanding
  • The debt/assets ratio for STIM is higher compared to a year ago.
STIM Yearly Shares OutstandingSTIM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
STIM Yearly Total Debt VS Total AssetsSTIM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M

2.2 Solvency

  • Based on the Altman-Z score of -3.50, we must say that STIM is in the distress zone and has some risk of bankruptcy.
  • STIM's Altman-Z score of -3.50 is on the low side compared to the rest of the industry. STIM is outperformed by 66.14% of its industry peers.
  • A Debt/Equity ratio of 2.94 is on the high side and indicates that STIM has dependencies on debt financing.
  • STIM has a Debt to Equity ratio of 2.94. This is amonst the worse of the industry: STIM underperforms 83.60% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.94
Debt/FCF N/A
Altman-Z -3.5
ROIC/WACCN/A
WACC12.39%
STIM Yearly LT Debt VS Equity VS FCFSTIM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M 80M

2.3 Liquidity

  • A Current Ratio of 2.02 indicates that STIM has no problem at all paying its short term obligations.
  • STIM has a Current ratio of 2.02. This is in the lower half of the industry: STIM underperforms 62.96% of its industry peers.
  • A Quick Ratio of 1.87 indicates that STIM should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.87, STIM is in line with its industry, outperforming 49.21% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.02
Quick Ratio 1.87
STIM Yearly Current Assets VS Current LiabilitesSTIM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. STIM Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 56.93% over the past year.
  • Looking at the last year, STIM shows a very strong growth in Revenue. The Revenue has grown by 99.17%.
  • STIM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.81% yearly.
EPS 1Y (TTM)56.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.7%
Revenue 1Y (TTM)99.17%
Revenue growth 3Y31.76%
Revenue growth 5Y24.81%
Sales Q2Q%85.73%

3.2 Future

  • STIM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.26% yearly.
  • Based on estimates for the next years, STIM will show a quite strong growth in Revenue. The Revenue will grow by 12.54% on average per year.
EPS Next Y20.47%
EPS Next 2Y19.8%
EPS Next 3Y25.26%
EPS Next 5YN/A
Revenue Next Year10.13%
Revenue Next 2Y10.88%
Revenue Next 3Y12.71%
Revenue Next 5Y12.54%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
STIM Yearly Revenue VS EstimatesSTIM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 50M 100M 150M 200M
STIM Yearly EPS VS EstimatesSTIM Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. STIM Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for STIM. In the last year negative earnings were reported.
  • Also next year STIM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
STIM Price Earnings VS Forward Price EarningsSTIM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
STIM Per share dataSTIM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5 2

4.3 Compensation for Growth

  • STIM's earnings are expected to grow with 25.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.8%
EPS Next 3Y25.26%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. STIM Dividend Analysis

5.1 Amount

  • STIM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

STIM Fundamentals: All Metrics, Ratios and Statistics

NEURONETICS INC

NASDAQ:STIM (3/27/2026, 8:00:00 PM)

After market: 1.2995 +0.01 (+0.74%)

1.29

-0.04 (-3.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-17
Earnings (Next)05-04
Inst Owners34.72%
Inst Owner Change102.58%
Ins Owners17.3%
Ins Owner Change14.95%
Market Cap88.35M
Revenue(TTM)149.16M
Net Income(TTM)-39.00M
Analysts82.22
Price Target3.06 (137.21%)
Short Float %28.32%
Short Ratio5.38
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.74%
Min EPS beat(2)-0.62%
Max EPS beat(2)8.09%
EPS beat(4)1
Avg EPS beat(4)-37.26%
Min EPS beat(4)-91.81%
Max EPS beat(4)8.09%
EPS beat(8)2
Avg EPS beat(8)-36.98%
EPS beat(12)5
Avg EPS beat(12)-17.97%
EPS beat(16)8
Avg EPS beat(16)-9.46%
Revenue beat(2)1
Avg Revenue beat(2)-1.33%
Min Revenue beat(2)-3.39%
Max Revenue beat(2)0.72%
Revenue beat(4)3
Avg Revenue beat(4)1.67%
Min Revenue beat(4)-3.39%
Max Revenue beat(4)7.85%
Revenue beat(8)4
Avg Revenue beat(8)0.02%
Revenue beat(12)6
Avg Revenue beat(12)0%
Revenue beat(16)10
Avg Revenue beat(16)1.29%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.59
P/FCF N/A
P/OCF N/A
P/B 3.95
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.59
EYN/A
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-0.31
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS2.18
BVpS0.33
TBVpS-0.28
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -27.55%
ROE -174.27%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.48%
FCFM N/A
ROA(3y)-28.21%
ROA(5y)-27.7%
ROE(3y)-140.11%
ROE(5y)-104.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.01%
GM growth 5Y-8.73%
F-Score4
Asset Turnover1.05
Health
Industry RankSector Rank
Debt/Equity 2.94
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 23.12%
Cap/Sales 0.54%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.02
Quick Ratio 1.87
Altman-Z -3.5
F-Score4
WACC12.39%
ROIC/WACCN/A
Cap/Depr(3y)70.64%
Cap/Depr(5y)126.36%
Cap/Sales(3y)1.94%
Cap/Sales(5y)3.02%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.7%
EPS Next Y20.47%
EPS Next 2Y19.8%
EPS Next 3Y25.26%
EPS Next 5YN/A
Revenue 1Y (TTM)99.17%
Revenue growth 3Y31.76%
Revenue growth 5Y24.81%
Sales Q2Q%85.73%
Revenue Next Year10.13%
Revenue Next 2Y10.88%
Revenue Next 3Y12.71%
Revenue Next 5Y12.54%
EBIT growth 1Y-2.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year64.43%
EBIT Next 3Y21.54%
EBIT Next 5Y17.59%
FCF growth 1Y34.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.27%
OCF growth 3YN/A
OCF growth 5YN/A

NEURONETICS INC / STIM Fundamental Analysis FAQ

What is the ChartMill fundamental rating of NEURONETICS INC (STIM) stock?

ChartMill assigns a fundamental rating of 2 / 10 to STIM.


What is the valuation status of NEURONETICS INC (STIM) stock?

ChartMill assigns a valuation rating of 1 / 10 to NEURONETICS INC (STIM). This can be considered as Overvalued.


Can you provide the profitability details for NEURONETICS INC?

NEURONETICS INC (STIM) has a profitability rating of 1 / 10.


What is the earnings growth outlook for NEURONETICS INC?

The Earnings per Share (EPS) of NEURONETICS INC (STIM) is expected to grow by 20.47% in the next year.